Covis Pharma

Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial, which assessed the efficacy of two chronic obstructive pulmonary disorder (COPD) therapies, Duaklir (aclidinium bromide 400µg/formoterol 12µg twice-daily) and Eklira/Tudorza (aclidinium bromide 400µg twice-daily), compared to placebo. The trial, which recruited 70% of patients from…